Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use of Protein-Based Vaccines Expressing Recombinant Measles and Mumps Immunogens for Human Use To Prevent Measles and/or Mumps Infections, Disease, and Transmission, 26927 [2021-10469]

Download as PDF Federal Register / Vol. 86, No. 94 / Tuesday, May 18, 2021 / Notices National Institutes of Health, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435–1850, limc4@csr.nih.gov. Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Pathobiology of Kidney Disease Study Section. Date: June 23–24, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Atul Sahai, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, 301–435– 1198, sahaia@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Biology and Immunology of Bacteria and Other Pathogens. Date: June 23, 2021. Time: 10:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jingsheng Tuo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3196, Bethesda, MD 20892, 301–451–5953, tuoj@ csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 15, 2021. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–10427 Filed 5–17–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use of ProteinBased Vaccines Expressing Recombinant Measles and Mumps Immunogens for Human Use To Prevent Measles and/or Mumps Infections, Disease, and Transmission jbell on DSKJLSW7X2PROD with NOTICES AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and SUMMARY: VerDate Sep<11>2014 16:40 May 17, 2021 Jkt 253001 Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Mevox, Ltd., located in Rugby, United Kingdom. DATES: Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases’ Technology Transfer and Intellectual Property Office on or before June 2, 2021 will be considered. ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Daniel Lee, J.D., Technology Transfer and Patent Specialist, National Institute of Allergy and Infectious Diseases Technology Transfer and Intellectual Property Office by email (daniel.lee5@nih.gov) or phone (301– 761–6327). SUPPLEMENTARY INFORMATION: Intellectual Property E–153–2019: Mumps and Measles Virus Immunogens and Their Use 1. United States Provisional Patent Application No. 62/946,902, filed 11 December 2019 (HHS Reference No. E– 153–2019–0–US–01); and 2. International Patent Application No. PCT/US2020/064619, filed 11 December 2020 (HHS Reference No. E– 153–2019–0–PCT–01). The patent and patent application rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the fields of use may be limited to the following: Development, commercialization, and use of proteinbased vaccines expressing recombinant measles and mumps immunogens for human use to prevent measles and/or mumps infections, disease, and transmission. This technology discloses the prefusion-stabilized recombinant MeV F glycoprotein trimers and MuV F glycoprotein trimers, as well as MuV prefusion F–HN chimeras for use as vaccines. This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Institute of Allergy and Infectious Diseases receives written evidence and PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 26927 argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent commercialization license. In response to this notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 12, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021–10469 Filed 5–17–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Review of PAR 18–078 Investigational New Drug (IND)-Enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol-Related Disorders (U44—Clinical Trial Optional). Date: June 4, 2021. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\18MYN1.SGM 18MYN1

Agencies

[Federal Register Volume 86, Number 94 (Tuesday, May 18, 2021)]
[Notices]
[Page 26927]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-10469]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development, 
Commercialization, and Use of Protein-Based Vaccines Expressing 
Recombinant Measles and Mumps Immunogens for Human Use To Prevent 
Measles and/or Mumps Infections, Disease, and Transmission

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an Exclusive Patent 
License to practice the inventions embodied in the Patents and Patent 
Applications listed in the Supplementary Information section of this 
Notice to Mevox, Ltd., located in Rugby, United Kingdom.

DATES: Only written comments and/or applications for a license which 
are received by the National Institute of Allergy and Infectious 
Diseases' Technology Transfer and Intellectual Property Office on or 
before June 2, 2021 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Daniel Lee, J.D., Technology Transfer and Patent 
Specialist, National Institute of Allergy and Infectious Diseases 
Technology Transfer and Intellectual Property Office by email 
([email protected]) or phone (301-761-6327).

SUPPLEMENTARY INFORMATION:

Intellectual Property

E-153-2019: Mumps and Measles Virus Immunogens and Their Use

    1. United States Provisional Patent Application No. 62/946,902, 
filed 11 December 2019 (HHS Reference No. E-153-2019-0-US-01); and
    2. International Patent Application No. PCT/US2020/064619, filed 11 
December 2020 (HHS Reference No. E-153-2019-0-PCT-01).
    The patent and patent application rights in these inventions have 
been assigned and/or exclusively licensed to the government of the 
United States of America.
    The prospective exclusive license territory may be worldwide and 
the fields of use may be limited to the following: Development, 
commercialization, and use of protein-based vaccines expressing 
recombinant measles and mumps immunogens for human use to prevent 
measles and/or mumps infections, disease, and transmission.
    This technology discloses the pre-fusion-stabilized recombinant MeV 
F glycoprotein trimers and MuV F glycoprotein trimers, as well as MuV 
prefusion F-HN chimeras for use as vaccines.
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published Notice, the National 
Institute of Allergy and Infectious Diseases receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 
404.
    Complete applications for a license in the prospective field of use 
that are timely filed in response to this notice will be treated as 
objections to the grant of the contemplated exclusive patent 
commercialization license. In response to this notice, the public may 
file comments or objections. Comments and objections, other than those 
in the form of a license application, will not be treated 
confidentially, and may be made publicly available. License 
applications submitted in response to this notice will be presumed to 
contain business confidential information and any release of 
information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: May 12, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-10469 Filed 5-17-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.